IQVIA · 2 days ago
Senior/Principal Statistical Programmer
Wonder how qualified you are to the job?
AnalyticsHealth Care
Insider Connection @IQVIA
Responsibilities
Design and execute clinical trials for drug development.
Collaborate with cross-functional teams on data analysis and interpretation.
Ensure compliance with regulatory requirements and industry standards.
Contribute to the successful implementation of clinical development programs.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
Substantial experience in statistical programming using SAS, R, or other relevant programming languages within the pharmaceutical or biotech industry.
Proven expertise in PK/PD data analysis and interpretation, including modeling and simulation.
Solid understanding of clinical trial designs, protocols, and regulatory requirements related to PK/PD endpoints.
Familiarity with industry standards such as CDISC data structures and guidelines for data submissions.
Strong analytical, problem-solving, and communication skills, with the ability to work effectively in cross-functional teams.
Detail-oriented with a commitment to producing high-quality deliver
Master's or Ph.D. in Biostatistics, Statistics, or a related field with a strong emphasis on pharmacokinetics (PK) and pharmacodynamics (PD) tables within tight timelines.
Company
IQVIA
IQVIA provides analytics, compliance, and management solutions to the life sciences industry.
H1B Sponsorship
IQVIA has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Trends of Total Sponsorships
2023 (218)
2022 (199)
2021 (286)
2020 (197)
Funding
Current Stage
Public CompanyTotal Funding
$1.5B2023-11-14Post Ipo Debt· $500M
2023-05-18Post Ipo Debt· $1B
2019-08-08Post Ipo Equity· Undisclosed
Leadership Team
Recent News
The Pharma Letter
2024-05-29
2024-05-05
2024-05-05
Company data provided by crunchbase